Skip to content

Sandoz gets positive Phase 3 results for Humira biosimilar

March 8, 2017

A Phase III study has shown that GP2017, which is manufactured by Sandoz, a unit of Novartis AG (ADR) (NYSE:NVS), has shown positive results as a Humira biosimilar. Data gleaned from the study shows that the biosimilar can be used to treat psoriasis that is in the moderate or severe stages. The results were presented in Orlando, Florida to an annual meeting of dermatologists.

The trial took a period of 51 weeks and it showed that at the 16th week, there was 75% improvement for the patients of psoriasis who took the biosimilar. Immunogenicity, safety and efficacy were the primary goals of the study.


From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: